Literature DB >> 8737597

Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.

D Mantle1, G Falkous, S Ishiura, P J Blanchard, E K Perry.   

Abstract

Neuronal death associated with plaque and tangle formation characteristic of Alzheimer's disease (AD) may result from an underlying defect of intracellular protein catabolism. In an attempt to identify the proteolytic enzyme types responsible for aberrant protein processing, we have composed the levels of activity of proline endopeptidase in brain tissue samples (grey/white matter) from frontal, parietal, temporal and occipital lobes, from normal control cases, and cases with AD, Lewy body dementia (LBD), Parkinson's disease (PD) and Huntington's disease (HD). The activity of proline endopeptidase was significantly reduced in AD to approximately 65% of that of corresponding control tissue-this is of note since previous biochemical analyses have in general failed to detect altered activity of other protease types in AD tissues. However, this relatively selective reduction in proline endopeptidase activity in AD tissue (in terms of protease types investigated) is not specific for disease type, since activity was also reduced (65%-70% of control) in tissue samples from LBD, PD and HD cases. The data suggest that reduction in proline endopeptidase activity may be a characteristic of a generalized process of neurodegeneration. Although the precise cellular function of this enzyme in normal/ pathological tissues remains to be determined, the question arises as to whether pharmacological strategies designed to enhance proline endopeptidase activity in brain tissue may improve patient outcome in the above disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8737597     DOI: 10.1016/0009-8981(96)06282-1

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  16 in total

1.  Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors.

Authors:  Tommi P Kilpeläinen; Jonna K Tyni; Maija K Lahtela-Kakkonen; Tony S Eteläinen; Timo T Myöhänen; Erik A A Wallén
Journal:  ACS Med Chem Lett       Date:  2019-11-11       Impact factor: 4.345

2.  Triosephosphate isomerase deficiency: consequences of an inherited mutation at mRNA, protein and metabolic levels.

Authors:  Judit Oláh; Ferenc Orosz; László G Puskás; László Hackler; Margit Horányi; László Polgár; Susan Hollán; Judit Ovádi
Journal:  Biochem J       Date:  2005-12-15       Impact factor: 3.857

3.  Distribution of immunoreactive prolyl oligopeptidase in human and rat brain.

Authors:  Timo T Myöhänen; Jarkko I Venäläinen; Erkki Tupala; J Arturo Garcia-Horsman; Riitta Miettinen; Pekka T Männistö
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 3.996

4.  Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction.

Authors:  Mari H Savolainen; Xu Yan; Timo T Myöhänen; Henri J Huttunen
Journal:  J Biol Chem       Date:  2015-01-02       Impact factor: 5.157

5.  Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse.

Authors:  Ulrika H Julku; Anne E Panhelainen; Saija E Tiilikainen; Reinis Svarcbahs; Anne E Tammimäki; T Petteri Piepponen; Mari H Savolainen; Timo T Myöhänen
Journal:  Mol Neurobiol       Date:  2016-12-13       Impact factor: 5.590

6.  Maternal influence of prolyl endopeptidase on fat mass of adult progeny.

Authors:  C H Warden; J S Fisler; G Espinal; J Graham; P J Havel; B Perroud
Journal:  Int J Obes (Lond)       Date:  2009-06-30       Impact factor: 5.095

7.  Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors.

Authors:  Timo T Myöhänen; Elisa Pyykkö; Pekka T Männistö; Olli Carpen
Journal:  J Histochem Cytochem       Date:  2012-06-26       Impact factor: 2.479

8.  The role of Thyrotropin Releasing Hormone in aging and neurodegenerative diseases.

Authors:  Caitlin M Daimon; Patrick Chirdon; Stuart Maudsley; Bronwen Martin
Journal:  Am J Alzheimers Dis (Columbia)       Date:  2013

9.  The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

Authors:  Mari H Savolainen; Christopher T Richie; Brandon K Harvey; Pekka T Männistö; Kathleen A Maguire-Zeiss; Timo T Myöhänen
Journal:  Neurobiol Dis       Date:  2014-04-16       Impact factor: 5.996

10.  Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues.

Authors:  Timo T Myöhänen; Jarkko I Venäläinen; J Arturo García-Horsman; Marjo Piltonen; Pekka T Männistö
Journal:  Histochem Cell Biol       Date:  2008-07-11       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.